John E. Sabga Foundation International Pancreatic Cancer Symposium 2023

PANCREATIC CANCER FACTS

Nearly 500,000 new cases of the most lethal of cancers, pancreatic, were newly diagnosed worldwide this year. In the United States, more than 62,000 Americans will be diagnosed with pancreatic cancer, and nearly 50,000 will die from this disease, making it the third leading cause of cancer-related death. With the best treatments currently available, the median survival for patients with advanced disease is about 10 months following diagnosis, and the 5-year survival rate is less than 9 percent of all patients. This set of statistics sounds bleak however, progress in the past decade has shown promise in extending life and fighting this cancer diagnosis.

There are other notable areas of future research not only in the U.S. but across the globe worth exploring for patients and families. They include:

Familial risk for pancreatic cancer and watching for newonset diabetes with weight loss.

Advances in neoadjuvant therapy before doing surgery. Patients that undergo neoadjuvant therapy and make it to surgery have >80% chance at 5-year survival.

Though the difficult work in early detection and therapy for pancreatic cancer is painstaking, we are continuing to make progress and look for dramatic, life-saving treatments that improve the lives of patients around the world. The changing standard of care for pancreatic cancer and the acceleration of techniques and technologies for early detection are opening a space for the field of cancer research to move aggressively forward from promise to actual practice.

This is terrific news for cancer patients and their families around the world!

SCHEDULE OF EVENTS

T H U R S D A Y

JOHN E. SABGA FOUNDATION

MARCH

12:30 PM - 6:30 PM 16

INTERNATIONAL PANCREATIC CANCER SYMPOSIUM

Hyatt Regency-Trinidad

MARCH

DAY 17 F R I D A Y

S A T U R D A Y

VISIT TO ST. JAMES NATIONAL RADIOTHERAPY CENTRE

EXPLORE LOCAL CULTURE

EVENING 18

MARCH

2ND HOPE GALA Amara Restaurant Woodside, Invaders Bay

SYMPOSIUM SYMPOSIUM INFORMATION INFORMATION

Douglas B. Evans, MD Medical College of Wisconsin

Personalizing Neoadjuvant Therapy for Pancreatic Cancer

Wayne Frederick, MD, MBA Howard University

Improving Surgical Outcomes for Pancreatic Cancer Patients

Peter Hosein, MD University of Miami, Miller School of Medicine

Targeting homologous recombination deficiency in pancreatic cancer beyond BRCA

Colin Weekes, MD, PhD

Harvard Medical School

Harnessing Tumor Heterogeneity for Therapeutic Intent | New Onset Diabetes and Pancreatic Cancer

Jordan Winter, MD UH Cleveland Medical Center

Can forced hyperglycemia increase the potency of chemotherapy to pancreatic cancer?

Susan Tsai, MD,MHS

Medical College of Wisconsin

How to interpret CA19-9

Response for Patients with Localized Pancreatic Cancer

REGISTER NOW

The John E. Sabga Foundation is partnering with the Medical College of Wisconsin's LaBahn Pancreatic Cancer Program to innovate, educate, and share the latest in Pancreatic Cancer research and current care with the medical fraternity of Trinidad and Tobago and the Caribbean Region.

AACME ACCREDITED THROUGH TTMA

INFORMATION

HYATT REGENCY TRINIDAD

1 Wrightson Rd, Port of Spain, Trinidad & Tobago

12:30 PM TO 6:30 PM

Light lunch will be served

Cocktail reception to follow symposium

Thursday, March 16 2023

Dan, MBBS rsity of West Indies rator

Register using the below link: REGISTRATION bit.ly/JESSymp

For questions, contact us at: Jespancreaticfoundation@gmail com accommodations, click link below: yatt Regency Trinidad

MEET THE SPEAKERS

glas Evans is Chair of the Department of Surgery and came to MCW in 2009 from the University of Texas M D Anderson Cancer Center The Department of Surgery currently has over 110 faculty, approximately 70 residents and fellows and 117 advanced care practitioners. Dr. Evans has been involved in the research and treatment of pancreatic cancer for his entire career, with a special interest in treatment sequencing, clinical trials, surgical technique and translational research infrastructure. He is a member of the Review Panel for the Ontario Institute for Cancer Research and the National Advisory Committee of TGEN. He has been a member of the Scientific Review Committee for the PanCAN-AACR Career Development Awards and served as Scientific Review Committee Chair for the PanCAN-AACR Research Acceleration Network Awards.

Dr. Wayne A. I. Frederick was appointed the 17th president of Howard University in 2014 and was named the distinguished Charles R Drew Professor of Surgery by the Board of Trustees in 2020. Today, he continues to perform in the operating room and teach in the classroom. Dr. Frederick is a widely recognized expert on disparities in health care and medical education His medical research focuses on narrowing racial, ethnic and gender disparities in cancer care outcomes, especially in relation to gastrointestinal cancers. He also devotes his time to writing and speaking on salient topics in higher education and the underrepresentation of African-Americans in health care He also serves on numerous boards and committees including the U.S. Chamber of Commerce and the American Cancer Society as well as Humana Inc. and Insulet Corporation.

University of West Indies

Professor of Minimally Invasive Surgery

Professor Dan attended medical school at UWI, Mona and completed a general surgery residency at SUNY in Buffalo, New York. Following, he did a fellowship in advanced laparoscopic and bariatric surgery in Washington DC In 2003, he returned home to Trinidad and pioneered advanced laparoscopic and bariatric surgery in the Caribbean and in Trinidad. He joined the University of the West Indies in 2004 and was made Professor of Minimally Invasive Surgery in 2015 From 2015- 2021 he headed the Department of Clinical Surgical Sciences at UWI, following he assumed the post of Deputy Dean of Graduate Studies and Research.

Director, Surgical Services, UH Seidman Cancer Center; Division Chief, Surgical Oncology, UH Cleveland Medical Center; Professor

Dr. Winter is a nationally recognized, boardcertified surgeon with a special interest in the medical and surgical management of pancreatic and related cancers, pancreatic cysts, chronic pancreatitis, biliary, bile duct strictures, gastric and liver cancers and abdominal tumors. In addition to being a highly skilled clinician, Dr. Winter is a leader in translational and basic research. As director of the Winter Lab, which is funded by the American Cancer Society and the NIH, he is at the forefront of investigational efforts to find alternative treatments for pancreatic cancer.

Douglas B. Evans, MD

Donald C. Ausman Family Foundation Professor of Surgery and Chair, Department of Surgery

Medical College of Wisconsin

Wayne Frederick, MD, MBA

17th President of Howard University, Surgeon, Charles R. Drew Professor of Surgery

Howard University Jordan Winter, MD

UH Cleveland Medical Center

Dilip Dan, MBBS

MEET THE SPEAKERS CONT.

Peter Hosein, MD

Dr. Hosein sees patients with cancers of the esophagus, stomach, liver, bile ducts, colon, pancreas, small bowel, rectum and anal canal, in addition he sees GI neuroendocrine cancers He works closely with surgical oncologists, colorectal surgeons, radiation oncologists and interventional radiologists to provide multidisciplinary care for patients with gastrointestinal cancers. He is also a member of the HIPEC team (Hyperthermic Intraperitoneal Chemotherapy) for patients with peritoneal malignancies His primary research interest is in neoadjuvant therapy for patients with localized pancreatic cancer, and new therapies for metastatic pancreatic cancer.

Susan Tsai, MD,MHS

Medical College of Wisconsin

Professor, Department of Surgery, Division of Surgical Oncology; Director, LaBahn Pancreatic Cancer Program

Dr. Tsai is a Professor in the Division of Surgical Oncology, Department of Surgery and the Director of the LaBahn Pancreatic Cancer Program She is the Chief of Hepatopancreaticobiliary Surgery at the Clement J. Zablocki VA hospital. She did her medical school and residency training at the University of Michigan. She completed postdoctorate training in tumor immunology at the National Cancer Institute and completed a Surgical Oncology Fellowship at the Johns Hopkins Hospital She also received a Master’s in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. Her clinical expertise is in GI oncology with a focus on pancreatic cancer. Her research is focused on precision medicine clinical trials in pancreatic cancer and blood-based biomarkers.

Colin Weekes, MD, PhD

Harvard Medical School

Associate Professor, Medicine, Harvard Medical School; Director of Medical Pancreas Cancer Research

As Director for Medical Oncology Research for Pancreatic Cancer in the Tucker Gosnell Center for Gastrointestinal Cancers at MGH, Dr Weekes focuses on clinical and translational research in patients with pancreatic cancer. The goal of his area is to incorporate biologic principles into the treatment of patients with pancreas cancer. As such, he works with basic scientists to integrate targeted therapies and biomarkers of disease response into clinical trial development. In addition to his work in pancreas cancer, he also focus on early drug development for other GI malignancies.

Colin Weekes

Associate Professor of Clinical Medicine, Department of Medicine

University of Miami- Miller School of Medicine